免疫调节剂泊马度胺的药理作用和临床评价

Pharmacological mechanism and clinical studies of pomalidomide, a immunomodulatory

泊马度胺是新一代免疫调节剂,比沙利度胺和来那度胺更有效、毒性更小。2013年2月被美国食品和药物管理局批准用于治疗先前曾接受包括来那度胺和硼替佐米治疗但出现疾病进展的多发性骨髓瘤患者。本文对其药理作用、药动学、临床评价和不良反应等进行综述。

Pomalidomide, the newest immunomodulatory drug, was designed to be more potent and less toxic than thalidomide and lenalidomide. The US Food and Drug Administration approved the drug in February 2013 for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression. This paper reviewed the pharmacological effect, pharmacokinetics, clinical evaluation and adverse reaction of pomalidomide.